Evolutionary Genomics Inc
Evolutionary Genomics, Inc., together with its subsidiaries, engages in the research and identification of positively selected genes in humans, animals, and commercial crops. The company develops Adapted Traits Platform, a technology platform to identify genes for enhancing crop plant traits, such as yield, sugar content, biomass, drought tolerance, and pest/disease resistance. It serves governme… Read more
Evolutionary Genomics Inc (FNAM) - Total Liabilities
Latest total liabilities as of December 2022: $7.95 Million USD
Based on the latest financial reports, Evolutionary Genomics Inc (FNAM) has total liabilities worth $7.95 Million USD as of December 2022.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Evolutionary Genomics Inc - Total Liabilities Trend (2009–2022)
This chart illustrates how Evolutionary Genomics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Evolutionary Genomics Inc Competitors by Total Liabilities
The table below lists competitors of Evolutionary Genomics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Arcontech Group Plc
LSE:ARC
|
UK | GBX2.17 Million |
|
ConectiSys Corporation
PINK:CONC
|
USA | $5.00K |
|
Fidelity Emerging Markets Ord
LSE:FEML
|
UK | GBX16.96 Million |
|
Conn's, Inc.
NASDAQ:CONNQ
|
USA | $2.01 Billion |
|
Sterling Consolidated Corp
PINK:STCC
|
USA | $6.01 Million |
|
Block Energy PLC
LSE:BLOE
|
UK | GBX3.37 Million |
Liability Composition Analysis (2009–2022)
This chart breaks down Evolutionary Genomics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.92 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.42 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 3.38 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Evolutionary Genomics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Evolutionary Genomics Inc (2009–2022)
The table below shows the annual total liabilities of Evolutionary Genomics Inc from 2009 to 2022.
| Year | Total Liabilities | Change |
|---|---|---|
| 2022-12-31 | $3.92 Million | -46.51% |
| 2021-12-31 | $7.33 Million | +26.01% |
| 2020-12-31 | $5.82 Million | +27.14% |
| 2019-12-31 | $4.58 Million | +14.84% |
| 2018-12-31 | $3.99 Million | -0.27% |
| 2017-12-31 | $4.00 Million | -12.40% |
| 2016-12-31 | $4.56 Million | +1697.55% |
| 2015-12-31 | $253.75K | +1756.00% |
| 2014-12-31 | $13.67K | -82.51% |
| 2013-12-31 | $78.16K | +23.54% |
| 2012-12-31 | $63.27K | +29.48% |
| 2011-12-31 | $48.86K | +55.00% |
| 2010-12-31 | $31.52K | +18.59% |
| 2009-12-31 | $26.58K | -- |